For all of the hurdles that exist in the European industry, there is one particular avenue that has, so far at least, remained remarkably unexplored. That is undoubtedly the case on the financing finish.
Yes, European loved ones offices are conservative, and “equity” (at least as it is believed of in the North American sense) remains much less exciting in the no cost for all of public markets amongst Europeans compared to their cross Atlantic peers.
Having said that, for the suitable canna-entrepreneur, the most desirable issue about European financing so far has remained largely off the table. Namely tax credits, especially of the R&D and tech type (even though there are other sorts of credits on the table when crossing into connected fields.)
Yes, there are guidelines about this type of issue (and a lot of regulations). But as a automobile for assisting to offset the threat of evolving healthcare cannabis projects in unique, the pursuit of getting these tax credits has so far remained in its infancy.
It will not for lengthy.
Exactly where, Why and How Will This Influence Market Development?
For an market that so far has financed its highest fliers by way of the public equity markets (and exotic economic instruments like reverse mergers), the European financing possibilities now on the table are intriguing, if not significantly a lot more attractively legit.
Tax credits have currently shown up of course. The biggest firms from Canada are hip to this game. But increasingly so are the smaller sized players, and that is exactly where tax credits and other economic instruments and structures right here will start off to play a larger distinction.